Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia.
Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia.
复制标题
DOI：
10.1016/j.jiph.2021.04.006
复制
发表时间：
2021-07
影响因子：
6.7
通讯作者：
Aldibasi O
中科院分区：
文献类型：
--
作者：
Alharbi NK;Alghnam S;Algaissi A;Albalawi H;Alenazi MW;Albargawi AM;Alharbi AG;Alhazmi A;Al Qarni A;Alfarhan A;Zowawi HM;Alhatmi H;Alghamdi J;Alroqi F;Batarfi K;Arabi YM;Hashem AM;Bosaeed M;Aldibasi O
由严重急性呼吸道综合征-冠状病毒-2（SARS-CoV-2）引起的2019冠状病毒传染病（COVID-19）的估计血清阳性率是更好地评估病毒传播和监测COVID-19大流行在人群中的进展的关键证据。在沙特阿拉伯王国（KSA），SARS-CoV-2血清阳性率已在特定地区报告，但尚未报告广泛的全国性研究。在这里，我们报告了一项全国性的研究，以确定在大流行期间SARS-CoV-2在KSA人群中的流行率，使用来自王国六个不同地区的健康献血者，非COVID患者和医护人员（HCW）的血清样本，以及来自COVID-19患者的样本。从KSA的不同地区共收集了11，703份血清样本，包括：5395份来自剩余健康献血者的样本（D）; 5877份来自非COVID患者的样本（P），这些样本是通过临床生化实验室的非COVID患者的剩余血清收集的;以及400份来自同意的HCW的样本。为了确定SARS-CoV-2的血清阳性率，除了来自RT-PCR确认的COVID-19患者的阳性对照血清外，所有血清样本均采用样本合并策略进行内部ELISA，通过测试构成部分样本池的单个样本进一步验证，采用统计估计方法报告血清阳性率估计值。总体（结合D和P组）血清阳性率估计值在沙特阿拉伯约为11%;在麦加为5.1%（利雅得）、1.5%（贾赞）、18.4%（卡西姆）、20.8%（海尔）、14.7%（ER; Alahsa）和18.8%。麦加样本仅为D型，麦加和吉达市的检出率分别为24.4%和12.8%。沙特阿拉伯所有采样地区的血清阳性率将是报告的COVID-19感染率的12倍。在HCW中，7.5%（4.95-10.16 CI 95%）具有SARS-CoV-2反应性抗体，而没有报告任何先前确认的感染。这在高血压的HCW中更高。该研究还介绍了HCW和非COVID-19人群子集的人口统计学和合并症患病率。我们的研究估计，沙特阿拉伯全国COVID-19的血清学患病率为11%，地区之间存在明显差异。这表明无症状或轻度未报告的COVID-19病例的流行。
Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients. A total of 11,703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimates. Overall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the reported COVID-19 infection rate. Among HCWs, 7.5% (4.95–10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population. Our study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions. This indicates the prevalence of asymptomatic or mild unreported COVID-19 cases.
登录
查看更多内容
DOI：
10.3390/v12121390
发表时间：
2020-12-04
期刊：
Viruses
影响因子：
--
作者：
Hashem AM;Algaissi A;Almahboub SA;Alfaleh MA;Abujamel TS;Alamri SS;Alluhaybi KA;Hobani HI;AlHarbi RH;Alsulaiman RM;ElAssouli MZ;Hala S;Alharbi NK;Alhabbab RY;AlSaieedi AA;Abdulaal WH;Bukhari A;Al-Somali AA;Alofi FS;Khogeer AA;Pain A;Alkayyal AA;Almontashiri NAM;Ahmad BM;Li X
通讯作者：
Li X
影响因子：
15.9
作者：
Wang, Yanqun;Zhang, Lu;Zhao, Jincun
通讯作者：
Zhao, Jincun
影响因子：
11.8
作者：
Young, Barnaby E.;Ong, Sean W. X.;Lye, David Chien
通讯作者：
Lye, David Chien
影响因子：
168.9
作者：
Pollan, Marina;Perez-Gomez, Beatriz;Yotti, Raquel
通讯作者：
Yotti, Raquel
中国武汉市 138 例 2019 新型冠状病毒感染肺炎住院患者的临床特征。
影响因子：
120.7
作者：
Wang, Dawei;Hu, Bo;Peng, Zhiyong
通讯作者：
Peng, Zhiyong